134 related articles for article (PubMed ID: 22169503)
41. Treatment of recurrent hepatocellular carcinoma after liver transplantation.
Kim HR; Cheon SH; Rha SY; Lee S; Han KH; Chon CY; Lee JD; Sung JS; Chung HC
Asia Pac J Clin Oncol; 2011 Sep; 7(3):258-69. PubMed ID: 21884437
[TBL] [Abstract][Full Text] [Related]
42. Chemoembolization and bland embolization: a critical appraisal.
Befeler AS
Clin Liver Dis; 2005 May; 9(2):287-300, vii. PubMed ID: 15831274
[TBL] [Abstract][Full Text] [Related]
43. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma.
Tang ZY; Zhou XD; Ma ZC; Wu ZQ; Fan J; Qin LX; Yu Y
Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):495-8. PubMed ID: 15567731
[TBL] [Abstract][Full Text] [Related]
44. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
[TBL] [Abstract][Full Text] [Related]
45. Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
Liepe K; Brogsitter C; Leonhard J; Wunderlich G; Hliscs R; Pinkert J; Folprecht G; Kotzerke J
Jpn J Clin Oncol; 2007 Dec; 37(12):942-50. PubMed ID: 18094017
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.
Akamatsu M; Yoshida H; Obi S; Sato S; Koike Y; Fujishima T; Tateishi R; Imamura M; Hamamura K; Teratani T; Shiina S; Ishikawa T; Omata M
Liver Int; 2004 Dec; 24(6):625-9. PubMed ID: 15566514
[TBL] [Abstract][Full Text] [Related]
47. [Effects of adjuvant surgical therapy for continuous regional therapy for advanced hepatocellular carcinoma].
Nakano H; Sasaki Y; Imaoka S; Furukawa H; Ishikawa O; Kabuto T; Kameyama M; Hiratsuka M; Ohigashi H; Nakamori S
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1490-2. PubMed ID: 7574740
[TBL] [Abstract][Full Text] [Related]
48. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology.
Kudo M; Okanoue T;
Oncology; 2007; 72 Suppl 1():2-15. PubMed ID: 18087177
[TBL] [Abstract][Full Text] [Related]
49. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
Kudo M
Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
[TBL] [Abstract][Full Text] [Related]
50. Hepatocellular carcinoma downstaging in liver transplantation.
Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
[TBL] [Abstract][Full Text] [Related]
51. Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.
Kim JH; Yoon HK; Kim SY; Kim KM; Ko GY; Gwon DI; Sung KB
Aliment Pharmacol Ther; 2009 Jun; 29(12):1291-8. PubMed ID: 19392861
[TBL] [Abstract][Full Text] [Related]
52. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.
Carr BI
Liver Transpl; 2004 Feb; 10(2 Suppl 1):S107-10. PubMed ID: 14762849
[TBL] [Abstract][Full Text] [Related]
53. [Transcatheter arterial embolization with hepatic arterial induction of endogenous TNF in hepatocellular carcinoma].
Takekoshi H; Oyama R
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2845-8. PubMed ID: 2476966
[TBL] [Abstract][Full Text] [Related]
54. Management of spontaneous bleeding due to hepatocellular carcinoma.
Recordare A; Bonariol L; Caratozzolo E; Callegari F; Bruno G; Di Paola F; Bassi N
Minerva Chir; 2002 Jun; 57(3):347-56. PubMed ID: 12029230
[TBL] [Abstract][Full Text] [Related]
55. [Usefulness of hepatic arterial infusion chemotherapy using lecithin-added lipiodol emulsion in hepatocellular carcinoma].
Kobayashi S; Koizumi S; Katagiri S; Ariizumi S; Takahashi Y; Otsubo T; Takasaki K; Yamamoto M
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1433-7. PubMed ID: 17876141
[TBL] [Abstract][Full Text] [Related]
56. [Comparision of different interventional therapies for primary liver cancer].
Liu YM; Qin H; Wang CB; Fang XH; Ma QY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):232-5. PubMed ID: 17649645
[TBL] [Abstract][Full Text] [Related]
57. [Multidisciplinary treatment of unresectable liver cancer].
Saeki T; Kuninobu H; Kodama H; Nishiyama M; Yoshinaka K; Toge T; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1988 Aug; 15(8 Pt 2):2583-9. PubMed ID: 2843127
[TBL] [Abstract][Full Text] [Related]
58. Radionuclide therapy of hepatocellular carcinoma.
Keng GH; Sundram FX
Ann Acad Med Singap; 2003 Jul; 32(4):518-24. PubMed ID: 12968558
[TBL] [Abstract][Full Text] [Related]
59. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.
Rognoni C; Ciani O; Sommariva S; Bargellini I; Bhoori S; Cioni R; Facciorusso A; Golfieri R; Gramenzi A; Mazzaferro V; Mosconi C; Ponziani F; Sacco R; Trevisani F; Tarricone R
BMC Cancer; 2018 Jul; 18(1):715. PubMed ID: 29976149
[TBL] [Abstract][Full Text] [Related]
60. Practical considerations in the treatment of hepatocellular carcinoma.
Colleoni M; Audisio RA; De Braud F; Fazio N; Martinelli G; Goldhirsch A
Drugs; 1998 Mar; 55(3):367-82. PubMed ID: 9530543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
